GPC3 and neoplasm: Optimizing ADC design improves tumor targeting and penetration. GPC3- and CD24-targeting ADCs show promise in HCC, but poor prognosis and drug resistance remain challenges. Combining ADCs with immune checkpoint inhibitors may enhance outcomes.